Veradigm (MDRX) 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		185,090,723

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 77,251	$ 116,873
Accounts receivable, net of allowance of $35,264 and $31,266 as of September 30, 2016 and December 31, 2015, respectively	400,101	327,851
Prepaid expenses and other current assets	112,416	93,622
Total current assets	589,768	538,346
Long-term marketable securities	197,250	0
Fixed assets, net	144,804	125,617
Software development costs, net	140,025	85,775
Intangible assets, net	730,775	347,646
Goodwill	1,882,244	1,222,601
Deferred taxes, net	2,974	2,298
Other assets	122,297	359,665
Total assets	3,810,137	2,681,948
Current liabilities:
Accounts payable	93,236	60,004
Accrued expenses	85,336	62,021
Accrued compensation and benefits	52,773	62,398
Deferred revenue	370,821	315,925
Current maturities of long-term debt	12,051	12,178
Non-recourse current maturities of long-term debt - Netsmart	1,337	0
Current maturities of capital lease obligations	9,957	431
Total current liabilities	625,511	512,957
Long-term debt	663,089	612,405
Non-recourse long-term debt - Netsmart	533,589	0
Long-term capital lease obligations	13,096	617
Deferred revenue	18,155	20,273
Deferred taxes, net	155,860	22,164
Other liabilities	52,928	94,459
Total liabilities	2,062,228	1,262,875
Redeemable convertible non-controlling interest - Netsmart	377,494	0
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2016 and December 31, 2015	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2016 and December 31, 2015; 267,868 and 185,090 shares issued and outstanding as of September 30, 2016, respectively; 266,545 and 189,308 shares issued and outstanding as of December 31, 2015, respectively	2,679	2,665
Treasury stock: at cost, 82,778 and 77,237 shares as of September 30, 2016 and December 31, 2015, respectively	(260,834)	(189,753)
Additional paid-in capital	1,790,179	1,789,449
Accumulated deficit	(190,229)	(190,235)
Accumulated other comprehensive loss	(12,111)	(4,242)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,329,684	1,407,884
Non-controlling interest	40,731	11,189
Total stockholders’ equity	1,370,415	1,419,073
Total liabilities and stockholders’ equity	$ 3,810,137	$ 2,681,948

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 35,264	$ 31,266
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	267,868,000	266,545,000
Common stock, shares outstanding	185,090,000	189,308,000
Treasury stock at cost, shares	82,778,000	77,237,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Software delivery, support and maintenance	$ 252,692	$ 230,754	$ 731,721	$ 690,783
Client services	139,692	123,722	392,742	349,963
Total revenue	392,384	354,476	1,124,463	1,040,746
Cost of revenue:
Software delivery, support and maintenance	86,537	70,775	240,860	223,188
Client services	116,415	109,006	335,957	327,790
Amortization of software development and acquisition-related assets	23,273	21,347	62,905	63,006
Total cost of revenue	226,225	201,128	639,722	613,984
Gross profit	166,159	153,348	484,741	426,762
Selling, general and administrative expenses	98,778	91,043	277,733	259,821
Research and development	45,142	47,702	140,070	138,796
Asset impairment charges	0	22	4,650	341
Amortization of intangible and acquisition-related assets	5,365	5,712	14,944	19,039
Income from operations	16,874	8,869	47,344	8,765
Interest expense	(19,367)	(9,254)	(42,757)	(23,993)
Other (expense) income, net	(6)	423	466	2,281
Equity in net loss of unconsolidated investments	0	(1,479)	(7,501)	(1,303)
Loss before income taxes	(2,499)	(1,441)	(2,448)	(14,250)
Income tax benefit (provision)	2,656	(3,692)	2,596	(4,183)
Net income (loss)	157	(5,133)	148	(18,433)
Less: Net income attributable to non-controlling interest	(151)	(111)	(142)	(120)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,191)	0	(18,344)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,185)	$ (5,244)	$ (18,338)	$ (18,553)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.06)	$ (0.03)	$ (0.10)	$ (0.10)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.06)	$ (0.03)	$ (0.10)	$ (0.10)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 157	$ (5,133)	$ 148	$ (18,433)
Other comprehensive income (loss):
Foreign currency translation adjustments	150	(1,482)	(49)	(1,873)
Change in unrealized loss on marketable securities	9,750	0	(8,365)	(228)
Change in fair value of derivatives qualifying as cash flow hedges	686	(225)	900	5
Other comprehensive income (loss) before income tax expense	10,586	(1,707)	(7,514)	(2,096)
Income tax (expense) benefit related to items in other comprehensive income (loss)	(270)	88	(355)	86
Total other comprehensive income (loss)	10,316	(1,619)	(7,869)	(2,010)
Comprehensive income (loss)	10,473	(6,752)	(7,721)	(20,443)
Less: Comprehensive income attributable to non-controlling interest	(151)	(111)	(142)	(120)
Comprehensive income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 10,322	$ (6,863)	$ (7,863)	$ (20,563)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 148	$ (18,433)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	120,473	124,486
Stock-based compensation expense	29,717	27,225
Excess tax benefits from stock-based compensation	(972)	(346)
Deferred taxes	(4,198)	2,323
Asset impairment charges	4,650	341
Other losses, net	9,558	2,288
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(12,723)	7,060
Prepaid expenses and other assets	3,381	11,730
Accounts payable	26,341	(2,050)
Accrued expenses	(8,843)	(17,789)
Accrued compensation and benefits	(12,933)	(4,672)
Deferred revenue	30,587	(2,760)
Other liabilities	(28)	(1,090)
Net cash provided by operating activities	185,158	128,313
Cash flows from investing activities:
Capital expenditures	(25,046)	(14,211)
Capitalized software	(69,994)	(32,696)
Purchases of equity securities, other investments and related intangible assets	(20,685)	(212,654)
Sales and maturities of marketable securities and other investments	0	3,763
Cash paid for business acquisitions, net of cash acquired	(935,280)	(9,372)
Proceeds received from sale of fixed assets	37	15
Net cash used in investing activities	(1,050,968)	(265,155)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	84	102,091
Proceeds from issuance of redeemable convertible preferred stock - Netsmart	333,606	0
Excess tax benefits from stock-based compensation	972	346
Taxes paid related to net share settlement of equity awards	(7,379)	(5,714)
Payments of capital lease obligations	(3,858)	(311)
Credit facility payments	(80,507)	(189,912)
Credit facility borrowings, net of issuance costs	654,135	269,719
Repurchase of common stock	(71,082)	0
Net cash provided by financing activities	825,971	176,219
Effect of exchange rate changes on cash and cash equivalents	217	(1,152)
Net (decrease) increase in cash and cash equivalents	(39,622)	38,225
Cash and cash equivalents, beginning of period	116,873	53,173
Cash and cash equivalents, end of period	77,251	91,398
Supplemental non-cash information:
Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock in Netsmart by Netsmart, Inc. management	$ 25,543	$ 0

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting mong other things, (i) will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled, (ii) will allow an employer to repurchase more of an employee’s shares for tax withholding purposes than it can today without triggering liability accounting and (iii) will allow a policy election to account for forfeitures as they occur. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combinations	2. Business Combinations Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement (the “Contribution Agreement”) with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”) to form a joint business entity, Nathan Holding LLC, a Delaware limited liability company (“Nathan”). The formation of Nathan was completed on April 19, 2016. As a result, pursuant to, and subject to the terms and conditions of, the Contribution Agreement, Nathan issued to Allscripts Class A Common Units in exchange for Allscripts contributing its Homecare TM The Nathan operating agreement provides that the Class A Preferred Units entitle the owners at any time and from time to time following the later of (A) the earlier of (I) the fifth anniversary of the effective date and (II) a change in control of Allscripts, and (B) the earlier of (I) the payment in full of the obligations under the credit facilities and the termination of any commitments thereunder or (II) with respect to any proposed redemption, such earlier date for such redemption consented to in writing by the required lenders under each of the credit facilities under which obligations remain unpaid or under which commitments continue, to redeem all or any portion of their Class A Preferred Units for cash at a price per Unit equal to the Class A Preferred liquidation preference for each such Class A Preferred Unit as of the date of such redemption. The liquidation preference is equal to the greater of (i) a return of the original issue price plus a preferred return (accruing on a daily basis at the rate of 11% per annum and compounding annually on the last day of each calendar year) or (ii) the as-converted value of Class A Common Units in Nathan. The consolidated statements of operations for the three and nine months periods ended September 30, 2016 give effect to the accretion of the 11% redemption preference as part of the calculation of net income (loss) attributable to Allscripts stockholders. Also on April 19, 2016, Nathan acquired Netsmart, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of March 20, 2016 (the “Merger Agreement”), by and among Nathan Intermediate LLC, a Delaware limited liability company and a wholly-owned subsidiary of Nathan (“Intermediate”), Nathan Merger Co., a Delaware corporation and a wholly-owned subsidiary of Intermediate (“Merger Sub”), Netsmart, Inc. and Genstar Capital Partners V, L.P., as the equityholders’ representative. Pursuant to the Merger Agreement, on April 19, 2016, Merger Sub was merged with and into Netsmart, Inc., with Netsmart, Inc. surviving as a wholly-owned subsidiary of Intermediate (the “Merger”). As a result of these transactions (the “Netsmart Transaction” or “Netsmart Acquisition”), the establishment of Nathan combined the Allscripts Homecare TM At the effective time of the Merger, Netsmart, Inc.’s common stock shares issued and outstanding immediately prior to the effective time were converted into the right to receive a pro rata share of $950 million, reduced by net debt and subject to working capital and other adjustments (the “Purchase Price”). Each vested outstanding option to acquire shares of Netsmart, Inc.’s common stock became entitled to receive a pro rata share of the Purchase Price, less applicable exercise prices of the options. Certain holders of shares of Netsmart, Inc.’s common stock, who were members of Netsmart, Inc.’s management, exchanged a portion of such shares for equity interests in Nathan, in lieu of receiving their pro rata share of the Purchase Price, and certain holders of options to purchase Netsmart, Inc.’s common stock, who were also members of Netsmart, Inc.’s management, invested a portion of such holder’s proceeds from the Merger in equity interests in Nathan (collectively, the “Rollover”). After the completion of the Merger and the Rollover, Allscripts owned 49.1%, GI Partners owned 47.2% and Netsmart’s management owned 3.7% of the outstanding equity interests in Netsmart, in each case on an as-converted basis. As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare TM Pursuant to the consolidation guidance in FASB Accounting Standards Codification (“ASC”) Topic 810, Consolidation The acquisition of Netsmart, Inc. by Nathan was completed for an aggregate Purchase Price of $937 million. The Purchase Price was funded by the sources of funds as described in the table below. The Netsmart term loans are non-recourse to Allscripts and its wholly-owned subsidiaries. A portion of the debt proceeds were used to extinguish Netsmart, Inc.’s existing debt of $325 million, including accrued interest and fees of $2 million. The sources of funds used in connection with the Netsmart Acquisition are as follows: (In thousands) Cash contribution for redeemable convertible non-controlling interest in Netsmart - GI Partners $ 333,606 Exchange of Netsmart, Inc.'s common stock for redeemable convertible non-controlling interest in Netsmart - Netsmart, Inc. management 25,543 Cash contribution from borrowings under revolver in exchange for common stock in Netsmart - Allscripts 43,782 Net borrowings under new term loans - Netsmart 534,135 Total funds used for the acquisition $ 937,066 Under the acquisition method of accounting, the fair value of consideration transferred for Netsmart, Inc. was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. Our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period (up to one year from the acquisition date). During the three months ended September 30, 2016, we recorded several measurement period adjustments, the largest of which included $12.0 million increase in intangible assets, $4.4 million increase in deferred taxes, net, $2.0 million decrease in accrued expenses, and $9.6 million decrease in the residual allocation to goodwill. During the three months ended September 30, 2016, we also recorded t he resulting adjustment to accumulated amortization associated with the change in the fair value of intangible assets. The amount of amortization expense adjustment related to the second quarter of 2016 was not material. The preliminary allocation of the fair value of the consideration transferred, including measurement period adjustments through September 30, 2016, is shown in the table below. The primary areas of the preliminary allocation of the fair value of consideration transferred that are not yet finalized relate to the finalization of certain tax-related balances and valuation estimates. (In thousands) Cash and cash equivalents $ 5,982 Accounts receivable, net 54,042 Prepaid expenses and other current assets 9,335 Fixed assets 26,829 Intangible assets 409,500 Goodwill 615,634 Other assets 6,889 Accounts payable (14,151 ) Accrued expenses (9,595 ) Deferred revenue (18,843 ) Capital lease obligations (17,833 ) Deferred taxes, net (127,050 ) Other liabilities (3,673 ) Net assets acquired $ 937,066 Allscripts’ contribution of its Homecare TM TM As noted above, the formation of Netsmart resulted in the merger of our Homecare TM The acquired intangible assets are being amortized over their useful lives, using a method that approximates the pattern of economic benefits to be gained by the intangible asset and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Technology 10-12 yrs $ 144,000 Corporate Trademark indefinite 27,000 Product Trademarks 10 yrs 8,500 Customer Relationships 12-20 yrs 230,000 $ 409,500 Acquisition costs related to the Netsmart acquisition are included in selling, general and administrative expenses in the accompanying consolidated statement of operations totaled $4.1 million for the nine months ended September 30, 2016. There were no acquisition-related costs recorded during the three months ended September 30, 2016. The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three and nine months ended September 30, 2016 and the supplemental pro forma revenue and net loss of the combined entity, presented as if the acquisition of Netsmart, Inc. had occurred on January 1, 2015, are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Actual from Netsmart since acquisition date of April 19, 2016: Revenue (1) $ 52,621 $ 0 $ 96,855 $ 0 Net loss (1) $ (11,126 ) $ 0 $ (18,239 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 399,811 $ 400,819 $ 1,198,048 $ 1,157,087 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (5,147 ) $ (21,223 ) $ (34,862 ) $ (88,933 ) Loss per share, basic and diluted $ (0.03 ) $ (0.11 ) $ (0.19 ) $ (0.48 ) (1) Amounts are not adjusted for the effects of transactions between us and Netsmart. The supplemental pro forma results were calculated after applying our accounting policies and adjusting the results of Netsmart to reflect (i) the additional depreciation and amortization that would have been charged resulting from the fair value adjustments to property, plant and equipment and intangible assets, (ii) the additional interest expense associated with Netsmart’s borrowings under the new term loans, and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value that would have been charged assuming the acquisition occurred on January 1, 2015, together with the consequential tax effects. Supplemental pro forma results for the nine months ended September 30, 2016 were also adjusted to exclude acquisition-related and transaction costs incurred during this period. Supplemental pro forma results for the nine months ended September 30, 2015 were adjusted to include these items. The supplemental pro forma results for the nine months ended September 30, 2016 exclude expenses incurred by Netsmart immediately prior to the Netsmart Transaction related to the accelerated pay-out of outstanding equity awards and the payment of seller costs. The effects of transactions between us and Netsmart during the periods presented have been eliminated in the supplemental pro forma data.

Fair Value Measurements and Inv

Fair Value Measurements and Investments	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	3. Fair Value Measurements and Investments We carry a portion of our financial assets and liabilities at fair value that are measured at a reporting date using an exit price (i.e., the price that would be received to sell an asset or paid to transfer a liability) and disclosed according to the quality of valuation inputs under the following hierarchy: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 40,804 $ 40,804 $ 0 $ 0 $ 80,208 $ 80,208 NantHealth Common Stock Long-term marketable securities 197,250 0 0 197,250 0 0 0 0 1.25% Embedded cash conversion option Other liabilities 0 0 (41,601 ) (41,601 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 1,324 0 1,324 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 197,250 $ 1,324 $ (797 ) $ 197,777 $ 0 $ 424 $ (1,002 ) $ (578 ) Investments On September 8, 2016, we acquired a majority interest in a third party for $29 million, net of cash acquired. This acquisition broadens our solution portfolio. The financial results of this third party were consolidated with our financial results starting on the date of the transaction. The preliminary allocations of the estimated fair value of the net assets of the third party to goodwill, intangibles and non-controlling interest were $45.2 million, $21.4 million and $29.4 million, respectively. The goodwill is not deductible for tax purposes. The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment September 30, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC (2) 0 $ 0 $ 0 $ 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 3 1,658 2,436 205,553 Cost method investments 5 29,991 26,041 17,876 Total equity investments 8 $ 31,649 $ 28,477 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. (2) As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method. Effective June 1, 2016, in preparation for an initial public offering (“IPO”) of its equity securities, Nant Health converted from an LLC into a Delaware corporation under the name of NantHealth, Inc. (“NantHealth”). We received 14,285,714 shares of common stock in the new corporation in replacement of our Series G Units of the former Nant Health LLC, representing a 12.6% ownership interest in NantHealth immediately prior to the IPO. On June 2, 2016, NantHealth completed its IPO of 6,500,000 shares and its stock began trading on the NASDAQ under the ticker symbol “NH”. The issuance of the IPO shares initially diluted our ownership interest to 11.8%. Also on June 2, 2016, we purchased an additional 714,286 shares at the IPO price of $14 per share for an additional investment in NantHealth of $10 million. This additional share purchase brought our total voting interest in NantHealth to 15,000,000 shares or 12.4% of the voting common stock. Based on the guidance under FASB ASC Topic 323, Investments – Equity Method and Joint Ventures In accordance with FASB ASC Topic 320, Investments – Debt and Equity Securities Fair Value Measurement The decline in the carrying value of our equity method investments from December 31, 2015 to September 30, 2016 was primarily due to NantHealth no longer being accounted for under the equity method as discussed above. The increase in the carrying value of our cost method investments from December 31, 2015 to September 30, 2016 was due to the acquisition of two additional non-marketable equity securities during the second quarter of 2016, as discussed below. This was offset by the recognition of an impairment charge of $2.1 million on one investment during the first quarter of 2016. During first quarter of 2016, we acquired a $0.5 million non-marketable convertible note of a third party with which we have an existing license and distribution agreement. This investment is accounted as an available-for-sale security with changes in fair value recorded in accumulated other comprehensive loss. The fair value of the convertible note was $0.5 million as of September 30, 2016 and was included in other assets in the accompanying consolidated balance sheet as of September 30, 2016. During second quarter of 2016, we acquired certain non-marketable equity securities of two third parties and entered into new commercial agreements with each of those third parties to license and distribute their products and services, for a total consideration of $10.2 million. Both of these equity investments acquired during the second quarter are accounted for under the cost method. The carrying value of these investments was $10.2 million as of September 30, 2016 and are included in other assets in the accompanying consolidated balance sheet. As of September 30, 2016, it is not practicable to estimate the fair value of our equity investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, Debt), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of September 30, 2016, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and nine months ended September 30, 2016 and 2015 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the table below includes stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2016 and 2015. Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 979 $ 972 $ 3,209 $ 3,247 Client services 884 824 3,512 3,554 Total cost of revenue 1,863 1,796 6,721 6,801 Selling, general and administrative expenses 6,464 5,649 17,972 15,860 Research and development 1,446 1,747 6,141 6,067 Total stock-based compensation expense $ 9,773 $ 9,192 $ 30,834 $ 28,728 Allscripts Stock-based Awards We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and nine months ended September 30, 2016 and 2015. We granted stock-based awards as follows: Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 24 $ 13.16 2,019 $ 13.14 Performance-based restricted stock units with a service condition 0 $ 0.00 545 $ 12.39 Market-based restricted stock units with a service condition 0 $ 0.00 621 $ 13.68 24 $ 13.16 3,185 $ 13.12 During the nine months ended September 30, 2016 and the year ended December 31, 2015, 1.3 million and 1.4 million shares of stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2016 and 2015 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2016 and 2015 were 572 thousand and 433 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases In November 2015, our Board of Directors authorized a stock repurchase program under which we may repurchase up to $150 million of our common stock through December 31, 2018. Any share repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. During the three and nine months ended September 30, 2016, we repurchased 1.5 million and 5.5 million Issuance of Warrants On June 30, 2016, we issued to a commercial partner, as part of an overall commercial relationship, unregistered warrants to purchase 900,000 shares of Company common stock, par value $0.01 per share at a price per share of $12.47, 1,000,000 shares of common stock at a price per share of $14.34, and 1,100,000 shares of common stock at a price per share of $15.59, in each case subject to customary anti-dilution adjustments. The warrants vest in four equal annual installments of 750 thousand shares beginning in June 2017 and expire in June 2026. Our issuance of the warrants was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Netsmart Long-Term Incentive Plan Netsmart has established the Nathan Holding LLC 2016 Unit Option Plan (the “Plan”) in order to provide key employees, managers, advisors and consultants of Netsmart and its affiliates with an opportunity to acquire an equity interest in Netsmart. The Plan provides for the maximum issuance of 116,491 thousand options related to Netsmart’s Class B Non-Voting Common Member Units (“Option Units”). The option unit grants may contain varying vesting conditions, including service, performance and market conditions established on a grant‑by‑grant basis as determined by the compensation committee of the board of directors and expire no more than 10 years after the date of grant. The Plan includes a call right which enables Netsmart to repurchase any outstanding units in the event of termination of employment. At September 30, 2016, there were 27,986 thousand Class B Non-Voting Common Units available for further issuance under the Plan. As discussed further below, for the period from April 19, 2016, the date of acquisition, through September 30, 2016, Netsmart issued 89,889 thousand Option Units to officers and employees at an exercise price of $1.00. Time Based During the period from April 19, 2016 through September 30, 2016, Netsmart granted 64,198 thousand Performance Based During the period from April 19, 2016 through September 30, 2016, Netsmart granted 25,691 thousand Option Units to certain of its executives and employees to reward the recipients if certain financial objectives are met. The Option Units were granted with an exercise price of $1.00 per Option Unit, which was equal to the fair value of Netsmart’s Common Units at the date of grant. During the same period, 395 thousand Performance Option Units were forfeited. In addition to a service condition, these Option Units only vest upon attaining certain performance and market conditions. There was no stock compensation expense recorded for these performance‑related Option Units, since achievement of the performance condition was not considered probable at September 30, 2016. A summary of the activity under the Plan is as follows: (Units in thousands) Option Units Weighted Average Exercise Price Granted during the period 89,889 $ 1.00 Options called during the period 0 $ 0.00 Options exercised during the period 0 $ 0.00 Forfeited during the period 1,384 $ 1.00 Outstanding – September 30, 2016 88,505 $ 1.00 Exercisable – September 30, 2016 0 $ 0.00 Option Units outstanding at September 30, 2016 are as follows: (Units in thousands) Outstanding Exercisable Exercise price Units Average Black-Scholes Value Weighted Average Remaining Life Shares Average Black-Scholes Value Weighted Average Remaining Life $ 1.00 88,505 $ 0.45 6.56 0 $ 0.00 0 As the current estimated fair value equals the exercise price of the Option Units as of September 30, 2016, there was no intrinsic value related to the outstanding Option Units. The compensation expense was included in the following categories in Netsmart’s statements of operations: (in thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Cost of revenue $ 64 $ 126 Research and development 43 79 Sales and marketing 81 174 General and administrative 1,536 2,771 Total $ 1,724 $ 3,150 At September 30, 2016 the liability for outstanding awards was $3.2 The fair value of Option Units granted during the period from April 19, 2016 through September 30, 2016 was estimated using the Black‑Scholes‑Merton option pricing model using the following weighted average assumptions: Average expected term in years 6.56 Risk free rate (weighted average) 1.4 % Expected dividends 0.0 % Average volatility 43.8 % Netsmart determined the estimated share price of $1.00 at September 30 , The expected term of the awards was determined based upon an estimate of the expected term of “plain vanilla” options as prescribed by the simplified method. The risk‑free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Netsmart estimates expected volatility based primarily on historical monthly volatility of comparable companies that are publicly traded. Netsmart has $25.4 million of share‑based compensation expense remaining to be recognized (based on the September 30, 2016 fair value) over future periods as follows: $1.8 million in 2016, $7.1 million in 2017, $7.1 million in 2018, $7.1 million in 2019, and $2.3 million in 2020.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Basic Loss per Common Share: Net income (loss) $ 157 $ (5,133 ) $ 148 $ (18,433 ) Less: Net income attributable to non-controlling interest $ (151 ) $ (111 ) $ (142 ) $ (120 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (10,191 ) $ 0 $ (18,344 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,185 ) $ (5,244 ) $ (18,338 ) $ (18,553 ) Weighted-average common shares outstanding 186,226 188,944 187,190 183,725 Basic Loss per Common Share $ (0.06 ) $ (0.03 ) $ (0.10 ) $ (0.10 ) Diluted Loss per Common Share: Net income (loss) $ 157 $ (5,133 ) $ 148 $ (18,433 ) Less: Net income attributable to non-controlling interest $ (151 ) $ (111 ) $ (142 ) $ (120 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (10,191 ) $ 0 $ (18,344 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,185 ) $ (5,244 ) $ (18,338 ) $ (18,553 ) Weighted-average common shares outstanding 186,226 188,944 187,190 183,725 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 186,226 188,944 187,190 183,725 Diluted Loss per Common Share $ (0.06 ) $ (0.03 ) $ (0.10 ) $ (0.10 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three and nine months ended September 30, 2016 and 2015, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 27,580 23,562 26,219 25,359

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: September 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 604,540 $ (333,904 ) $ 270,636 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 801,253 (420,114 ) 381,139 552,395 (405,317 ) 147,078 Total $ 1,405,793 $ (754,018 ) $ 651,775 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 52,000 Goodwill 1,882,244 1,222,601 Total $ 1,961,244 $ 1,274,601 During 2016, we made several changes to our organizational and reporting structure. Refer to Note 13, “Business Segments” for additional information. As a result of these changes, we assessed our revised reporting units and allocated the goodwill previously assigned to our former Touchworks reporting unit to our new Acute and Ambulatory reporting units based on the relative fair value allocation method as applied to the separate Touchworks acute and ambulatory businesses. During the second quarter of 2016, we completed the Netsmart Transaction and recorded additional goodwill and intangible assets relating to the acquisition of Netsmart, Inc. As noted above, the formation of Netsmart resulted in the merger of our Homecare TM TM TM We performed our annual goodwill impairment test as of October 1, 2015, our annual testing date. We also performed interim goodwill impairment tests as of January 1, 2016 in conjunction with the organizational change within our Clinical and Financial Solutions reportable segment, as of March 31, 2016 in conjunction with the Netsmart Transaction and related carve-out of our Homecare TM ® TM TM TM TM TM ® TM ® TM Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 0 $ 1,222,601 Additions arising from business acquisitions: Netsmart 0 0 615,634 615,634 Other 45,220 0 0 45,220 Total additions to goodwill 45,220 0 615,634 660,854 Reallocation 0 (37,600 ) 37,600 0 Foreign exchange translation (1,211 ) 0 0 (1,211 ) Balance as of September 30, 2016 $ 840,376 $ 388,634 $ 653,234 $ 1,882,244 In connection with our acquisition of Netsmart, during the nine months ended September 30, 2016, we recognized goodwill of $615.6 million. The goodwill reallocation during the nine months ended September 30, 2016 relates to the allocation of goodwill associated with our Homecare TM Other additions during the nine months ended relate to goodwill arising from our acquisition of a majority interest in a third party during the three months ended September 30, 2016. There were no accumulated impairment losses associated with our goodwill as of September 30, 2016 or December 31, 2015.

Asset Impairment Charges

Asset Impairment Charges	9 Months Ended
	Sep. 30, 2016
Asset Impairment Charges [Abstract]
Asset Impairment Charges	7. Asset Impairment Charges We incurred the following impairment charges: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Asset impairment charges $ 0 $ 22 $ 4,650 $ 341 During the nine months ended September 30, 2016, we incurred non-cash asset impairment charges totaling $4.7 million, all of which were incurred in the first quarter of 2016. Included in these charges was $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. Asset impairment charges for the nine months ended September 30, 2015 were not significant.

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consisted of the following: September 30, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 52,370 $ 292,630 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility 387,500 5,027 382,473 346,875 5,704 341,171 Netsmart Non-Recourse Debt: First Lien Term Loan 394,013 16,720 377,293 0 0 0 Second Lien Term Loan 167,000 9,367 157,633 0 0 0 Other debt 37 0 37 183 0 183 Total debt $ 1,293,550 $ 83,484 $ 1,210,066 $ 692,058 $ 67,475 $ 624,583 Less debt payable within one year - excluding Netsmart 12,538 487 12,051 12,657 479 12,178 Less debt payable within one year - Netsmart 3,950 2,613 1,337 0 0 0 Total long-term debt, less current maturities $ 1,277,062 $ 80,384 $ 1,196,678 $ 679,401 $ 66,996 $ 612,405 Interest expense consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Interest expense $ 3,896 $ 4,370 $ 11,029 $ 12,239 Amortization of discounts and debt issuance costs 3,522 3,508 10,401 10,321 Write off of unamortized deferred debt issuance costs 0 1,376 0 1,433 Netsmart: Interest expense (1) 11,019 0 19,549 0 Amortization of discounts and debt issuance costs 930 0 1,778 0 Total interest expense $ 19,367 $ 9,254 $ 42,757 $ 23,993 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 3,234 $ 3,234 Amortization of discounts and debt issuance costs 3,185 3,035 9,401 8,960 Total interest expense related to the 1.25% Notes $ 4,263 $ 4,113 $ 12,635 $ 12,194 Allscripts Senior Secured Facility As of September 30, 2016, $237.5 million under a term loan, $150.0 million under our revolving credit facility, and $0.8 million in letters of credit were outstanding under our senior secured credit facility. As of September 30, 2016, the interest rate on the United States dollars-denominated borrowings under our senior secured credit facility was LIBOR plus 2.00%, which totaled 2.52%. We were in compliance with all covenants under the senior secured credit facility agreement as of September 30, 2016. As of September 30, 2016, we had $399.2 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of September 30, 2016, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. Netsmart Non-Recourse Debt On April 19, 2016, Netsmart entered into a First and Second Lien Credit Agreement (the “Netsmart First Lien Credit Agreement” and the “Netsmart Second Lien Credit Agreement”, respectively), with a syndicate of financial institutions and UBS AG, Stamford Branch, as administrative agent. The Netsmart First Lien Credit Agreement provides for a $395 million senior secured 7-year term loan credit facility (the “Netsmart First Lien Term Loan”) and a $50 million senior secured 5-year revolving loan credit facility (the “Netsmart Revolving Facility”). The Netsmart Second Lien Credit Agreement provides for a $167 million senior secured 7.5-year term loan credit facility (the “Netsmart Second Lien Term Loan,” and, together with the Netsmart First Lien Credit Agreement, the “Netsmart Credit Agreements”). Each of Netsmart’s obligations under the Netsmart Credit Agreements are guaranteed by Intermediate, each other Borrower, each Subsidiary Guarantor and any other person who becomes a party to the Netsmart Credit Agreements, under an unconditional guaranty. Netsmart’s debt under the Netsmart Credit Agreements is non-recourse to Allscripts and its wholly-owned subsidiaries. The Netsmart Revolving Facility will terminate on April 19, 2021 and the Netsmart First Lien Term Loan matures on April 19, 2023. The Netsmart Second Lien Term Loan matures on October 19, 2023. All unpaid principal of, and interest accrued on, such loans must be repaid on their respective maturity dates. The outstanding principal amount of the Netsmart First Lien Term Loan and the Netsmart Revolving Facility bear interest at a rate equal to (a) with respect to LIBO Rate Loans, Adjusted LIBO Rate plus 4.75% and (b) with respect to ABR Loans, 3.75% (provided, however, that in respect of the Netsmart Revolving Loans, such rate may step-down to 4.25% and 3.25%, respectively, depending on the then-applicable leverage ratio). The outstanding principal amount of the Netsmart Second Lien Term Loan bears interest at a rate equal to (a) with respect to LIBO Rate Loans, Adjusted LIBO Rate plus 9.50% and (b) with respect to ABR Loans, 8.50%. The proceeds from the funding of the Netsmart Credit Agreements were used to, inter alia The Netsmart Credit Agreements contain a financial covenant that Intermediate and its subsidiaries maintain a maximum ratio of total debt to Consolidated Adjusted EBITDA. The entire principal amount of the Netsmart Credit Agreements and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs. Events of default under the Netsmart Credit Agreements include (but are not limited to) failure to make payments when due, a default in the performance of any covenants in the Netsmart Credit Agreements or related documents or certain changes of control of Intermediate and/or of Netsmart. The Netsmart First Lien Credit Agreement Netsmart Second Lien Credit Agreement In connection with the Netsmart Credit Agreements, during the second quarter of 2016, Netsmart incurred fees and other costs totaling $27.9 million, which were capitalized and included in the net borrowings outstanding under Netsmart’s Credit Agreements as of September 30, 2016. As of September 30, 2016, $394.0 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and $1.5 million in letters of credit under the Netsmart Revolving Facility were outstanding. As of September 30, 2016, the interest rate on the borrowings under the Netsmart First Lien Term Loan and the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 5.75%. As of September 30, 2016, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.5%, which totaled 10.5%. Netsmart was in compliance with all covenants under its Credit Agreements as of September 30, 2016. As of September 30, 2016, Netsmart had $48.5 million available, net of outstanding letters of credit, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes our future payment obligations under our debt as of September 30, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 $ 0 Term Loan 237,500 3,125 15,625 28,125 40,625 150,000 0 Revolving Facility 150,000 0 0 0 0 150,000 0 Netsmart Non-Recourse Debt: First Lien Term Loan 394,013 988 3,952 3,952 3,952 3,952 377,217 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Other debt 37 37 0 0 0 0 0 Total debt $ 1,293,550 $ 4,150 $ 19,577 $ 32,077 $ 44,577 $ 648,952 $ 544,217 (1)

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Loss before income taxes $ (2,499 ) $ (1,441 ) $ (2,448 ) $ (14,250 ) Income tax benefit (provision) $ 2,656 $ (3,692 ) $ 2,596 $ (4,183 ) Effective tax rate 106.3 % (256.2 %) 106.0 % (29.4 %) Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three and nine months ended September 30, 2016, compared with the prior year comparable periods, differs primarily due to release of valuation allowance of $1.4 million in the three and nine months ended September 30, 2016, compared to valuation allowance of $5.9 million recorded in the three and nine months ended September 30, 2015. Additionally, no estimate of the research and development credit was included in the effective tax rate for the three and nine months ended September 30, 2015 as the credit had not been reinstated for 2015 until December 18, 2015. Lastly, the effective tax rate for the three and nine months ended September 30, 2016, was impacted by the consolidation of Netsmart’s financial results starting on April 19, 2016. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Our unrecognized income tax benefits were $11.5 million and $11.8 million as of September 30, 2016 and December 31, 2015, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,324 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 40,804 N/A 1.25% Embedded cash conversion option N/A Other liabilities 41,601 Total derivatives $ 42,128 $ 41,601 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts Starting in 2015, we entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of September 30, 2016, there were 21 forward contracts outstanding that were staggered to mature monthly starting in October 2016 and ending in December 2017. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2017. As of September 30, 2016, the notional amounts of outstanding forward contracts ranged from 20 million to 120 million INR, or the equivalent of $0.3 million to $1.8 million, based on the exchange rate between the United States dollar and the INR in effect as of September 30, 2016. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three and nine months ended September 30, 2016, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of September 30, 2016, we estimate that $1.1 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Foreign exchange contracts $ 971 $ 1,172 Cost of Revenue $ 88 $ 84 Selling, general and administrative expenses 71 68 Research and development 126 120 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Foreign exchange contracts $ (317 ) $ (87 ) Cost of Revenue $ (29 ) $ (29 ) Selling, general and administrative expenses (23 ) (23 ) Research and development (40 ) (40 ) 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 1.25% Call Option $ 2,306 $ (18,277 ) $ (39,404 ) $ (8,422 ) 1.25% Embedded cash conversion option (2,362 ) 18,404 39,609 8,390 Net gain (loss) included in other income, net $ (56 ) $ 127 $ 205 $ (32 )

Other Comprehensive Income

Other Comprehensive Income	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Marketable Securities (3) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (49 ) (8,365 ) 710 (7,704 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 (165 ) (165 ) Net other comprehensive (loss) income (49 ) (8,365 ) 545 (7,869 ) Balance as of September 30, 2016 (2) $ (4,549 ) $ (8,365 ) $ 803 $ (12,111 ) (1) (2) (3) Marketable securities represent NantHealth common stock (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive (loss) income before reclassifications (1,873 ) 0 (53 ) (1,926 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 56 (84 ) Net other comprehensive (loss) income (1,873 ) (140 ) 3 (2,010 ) Balance as of September 30, 2015 (2) $ (3,992 ) $ 0 $ 3 $ (3,989 ) (1) (2) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 150 $ 0 $ 150 $ (1,482 ) $ 0 $ (1,482 ) Marketable securities: Net gain arising during the period 9,750 0 9,750 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on marketable securities 9,750 0 9,750 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period 971 (382 ) 589 (317 ) 124 (193 ) Net (gains) losses reclassified into income (285 ) 112 (173 ) 92 (36 ) 56 Net change in unrealized (losses) gains on foreign exchange contracts 686 (270 ) 416 (225 ) 88 (137 ) Net (loss) gain on cash flow hedges 686 (270 ) 416 (225 ) 88 (137 ) Other comprehensive (loss) income $ 10,586 $ (270 ) $ 10,316 $ (1,707 ) $ 88 $ (1,619 ) Nine Months Ended September 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (49 ) $ 0 $ (49 ) $ (1,873 ) $ 0 $ (1,873 ) Marketable securities: Net loss arising during the period (8,365 ) 0 (8,365 ) 0 0 0 Net (gain) loss reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized (losses) gains on marketable securities (8,365 ) 0 (8,365 ) (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,172 (462 ) 710 (87 ) 34 (53 ) Net (gains) losses reclassified into income (272 ) 107 (165 ) 92 (36 ) 56 Net change in unrealized gains (losses) on foreign exchange contracts 900 (355 ) 545 5 (2 ) 3 Net gain (loss) on cash flow hedges 900 (355 ) 545 5 (2 ) 3 Other comprehensive loss $ (7,514 ) $ (355 ) $ (7,869 ) $ (2,096 ) $ 86 $ (2,010 )

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred any material loss, or any material loss in excess of a recorded accrual, with respect to the following matters. Our management will continue to evaluate the potential exposure related to these matters in future periods. On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims. Trial has been scheduled for February 2017, and we will participate in court-ordered mediation prior to trial. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. After plaintiff’s motion to compel arbitration of the counterclaims was granted, Allscripts made a demand in arbitration where the counterclaims remain pending. Discovery in the proposed class action has now concluded. On March 31, 2016, plaintiff filed its motion for class certification.

Business Segments

Business Segments	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Business Segments	13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. During 2016, in an effort to further streamline and align our operating structure around our key ambulatory, acute and population health management solutions, we made several changes to our organizational and reporting structure. These changes included (i) the separation of the former Touchworks strategic business unit and its dedicated leadership team into acute and ambulatory businesses, and (ii) the transfer of several ancillary analytics-type products between our existing Clinical and Financial Solutions and Population Health reportable segments, both effective as of January 1, 2016, and (iii) the establishment of the FollowMyHealth® and EPSi TM In conjunction with these changes, we formed new Ambulatory and Acute strategic business units, which are deemed to be operating segments within the Clinical and Financial Solutions reportable segment. The ancillary products are extensions of our key ambulatory and acute solutions and in the future will be managed within the new Ambulatory and Acute strategic business units. Our FollowMyHealth® and EPSi TM Segment Reporting ® TM Effective on April 19, 2016, we completed the Netsmart Transaction which resulted in the formation of Netsmart through the merger of our Homecare TM TM TM Segment Reporting After the finalization of the above changes to our organizational and reporting structure, as of September 30, 2016, we had seven operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the new Ambulatory and Acute, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include Electronic Health Record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of three separate operating segments which include Population Health, FollowMyHealth ® TM Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The historical results of our Homecare TM Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Revenue: Clinical and Financial Solutions $ 276,503 $ 284,677 $ 829,656 $ 830,743 Population Health 61,722 54,405 171,347 165,038 Netsmart 52,621 0 96,854 0 Unallocated Amounts 1,538 15,394 26,606 44,965 Total revenue $ 392,384 $ 354,476 $ 1,124,463 $ 1,040,746 Gross Profit: Clinical and Financial Solutions $ 113,677 $ 120,855 $ 348,548 $ 331,828 Population Health 46,337 37,179 125,717 110,049 Netsmart 17,378 0 32,324 0 Unallocated Amounts (11,233 ) (4,686 ) (21,848 ) (15,115 ) Total gross profit $ 166,159 $ 153,348 $ 484,741 $ 426,762 Income (loss) from operations: Clinical and Financial Solutions $ 59,921 $ 66,184 $ 187,676 $ 166,607 Population Health 32,977 24,182 82,913 67,942 Netsmart (6,426 ) 0 (8,829 ) 0 Unallocated Amounts (69,598 ) (81,497 ) (214,416 ) (225,784 ) Total income (loss) from operations $ 16,874 $ 8,869 $ 47,344 $ 8,765

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On October 14, 2016, we acquired a 100% interest in a third party. The acquisition will broaden our Population Health solution portfolio. This transaction was not material to our consolidated financial position as of September 30, 2016. The financial results of this third party will be consolidated with our financial results starting on the date of the transaction. As of the date of this Form 10-Q, the preliminary allocation of the fair value of the consideration transferred is not yet been completed. On October 27, 2016, Netsmart announced the acquisition of a company that develops electronic medical record solutions for long-term and post-acute care. The financial results of this company will be consolidated with our financial results starting on the date of the transaction. As of the date of this Form 10-Q, the preliminary allocation of the fair value of the consideration transferred is not yet been completed.

Basis of Presentation and Sig21

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting mong other things, (i) will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled, (ii) will allow an employer to repurchase more of an employee’s shares for tax withholding purposes than it can today without triggering liability accounting and (iii) will allow a policy election to account for forfeitures as they occur. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2016
Assets Acquired and Liabilities Assumed	The preliminary allocation of the fair value of the consideration transferred, including measurement period adjustments through September 30, 2016, is shown in the table below. The primary areas of the preliminary allocation of the fair value of consideration transferred that are not yet finalized relate to the finalization of certain tax-related balances and valuation estimates. (In thousands) Cash and cash equivalents $ 5,982 Accounts receivable, net 54,042 Prepaid expenses and other current assets 9,335 Fixed assets 26,829 Intangible assets 409,500 Goodwill 615,634 Other assets 6,889 Accounts payable (14,151 ) Accrued expenses (9,595 ) Deferred revenue (18,843 ) Capital lease obligations (17,833 ) Deferred taxes, net (127,050 ) Other liabilities (3,673 ) Net assets acquired $ 937,066
Acquired Intangible Assets Amortization	The acquired intangible assets are being amortized over their useful lives, using a method that approximates the pattern of economic benefits to be gained by the intangible asset and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Technology 10-12 yrs $ 144,000 Corporate Trademark indefinite 27,000 Product Trademarks 10 yrs 8,500 Customer Relationships 12-20 yrs 230,000 $ 409,500
Netsmart [Member]
Sources of Funds Used in Acquisition	The sources of funds used in connection with the Netsmart Acquisition are as follows: (In thousands) Cash contribution for redeemable convertible non-controlling interest in Netsmart - GI Partners $ 333,606 Exchange of Netsmart, Inc.'s common stock for redeemable convertible non-controlling interest in Netsmart - Netsmart, Inc. management 25,543 Cash contribution from borrowings under revolver in exchange for common stock in Netsmart - Allscripts 43,782 Net borrowings under new term loans - Netsmart 534,135 Total funds used for the acquisition $ 937,066
Proforma Results	The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three and nine months ended September 30, 2016 and the supplemental pro forma revenue and net loss of the combined entity, presented as if the acquisition of Netsmart, Inc. had occurred on January 1, 2015, are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Actual from Netsmart since acquisition date of April 19, 2016: Revenue (1) $ 52,621 $ 0 $ 96,855 $ 0 Net loss (1) $ (11,126 ) $ 0 $ (18,239 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 399,811 $ 400,819 $ 1,198,048 $ 1,157,087 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (5,147 ) $ (21,223 ) $ (34,862 ) $ (88,933 ) Loss per share, basic and diluted $ (0.03 ) $ (0.11 ) $ (0.19 ) $ (0.48 )

Fair Value Measurements and I23

Fair Value Measurements and Investments (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet September 30, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 40,804 $ 40,804 $ 0 $ 0 $ 80,208 $ 80,208 NantHealth Common Stock Long-term marketable securities 197,250 0 0 197,250 0 0 0 0 1.25% Embedded cash conversion option Other liabilities 0 0 (41,601 ) (41,601 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 1,324 0 1,324 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 197,250 $ 1,324 $ (797 ) $ 197,777 $ 0 $ 424 $ (1,002 ) $ (578 )
Summary of Equity Investments Included in Other Assets	The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment September 30, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC (2) 0 $ 0 $ 0 $ 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 3 1,658 2,436 205,553 Cost method investments 5 29,991 26,041 17,876 Total equity investments 8 $ 31,649 $ 28,477 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. (2) As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Capital Unit [Line Items]
Stock-Based Compensation Expense	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 979 $ 972 $ 3,209 $ 3,247 Client services 884 824 3,512 3,554 Total cost of revenue 1,863 1,796 6,721 6,801 Selling, general and administrative expenses 6,464 5,649 17,972 15,860 Research and development 1,446 1,747 6,141 6,067 Total stock-based compensation expense $ 9,773 $ 9,192 $ 30,834 $ 28,728
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 24 $ 13.16 2,019 $ 13.14 Performance-based restricted stock units with a service condition 0 $ 0.00 545 $ 12.39 Market-based restricted stock units with a service condition 0 $ 0.00 621 $ 13.68 24 $ 13.16 3,185 $ 13.12
Netsmart [Member]
Capital Unit [Line Items]
Stock-Based Compensation Expense	The compensation expense was included in the following categories in Netsmart’s statements of operations: (in thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Cost of revenue $ 64 $ 126 Research and development 43 79 Sales and marketing 81 174 General and administrative 1,536 2,771 Total $ 1,724 $ 3,150
Netsmart [Member] | Class B Non Voting Common Units
Capital Unit [Line Items]
Schedule of Option Units Outstanding	Option Units outstanding at September 30, 2016 are as follows: (Units in thousands) Outstanding Exercisable Exercise price Units Average Black-Scholes Value Weighted Average Remaining Life Shares Average Black-Scholes Value Weighted Average Remaining Life $ 1.00 88,505 $ 0.45 6.56 0 $ 0.00 0
Schedule of Fair Value of Option Units Weighted Average Assumptions	The fair value of Option Units granted during the period from April 19, 2016 through September 30, 2016 was estimated using the Black‑Scholes‑Merton option pricing model using the following weighted average assumptions: Average expected term in years 6.56 Risk free rate (weighted average) 1.4 % Expected dividends 0.0 % Average volatility 43.8 %
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Capital Unit [Line Items]
Summary of the Activity Under the Plan	A summary of the activity under the Plan is as follows: (Units in thousands) Option Units Weighted Average Exercise Price Granted during the period 89,889 $ 1.00 Options called during the period 0 $ 0.00 Options exercised during the period 0 $ 0.00 Forfeited during the period 1,384 $ 1.00 Outstanding – September 30, 2016 88,505 $ 1.00 Exercisable – September 30, 2016 0 $ 0.00

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Basic Loss per Common Share: Net income (loss) $ 157 $ (5,133 ) $ 148 $ (18,433 ) Less: Net income attributable to non-controlling interest $ (151 ) $ (111 ) $ (142 ) $ (120 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (10,191 ) $ 0 $ (18,344 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,185 ) $ (5,244 ) $ (18,338 ) $ (18,553 ) Weighted-average common shares outstanding 186,226 188,944 187,190 183,725 Basic Loss per Common Share $ (0.06 ) $ (0.03 ) $ (0.10 ) $ (0.10 ) Diluted Loss per Common Share: Net income (loss) $ 157 $ (5,133 ) $ 148 $ (18,433 ) Less: Net income attributable to non-controlling interest $ (151 ) $ (111 ) $ (142 ) $ (120 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (10,191 ) $ 0 $ (18,344 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,185 ) $ (5,244 ) $ (18,338 ) $ (18,553 ) Weighted-average common shares outstanding 186,226 188,944 187,190 183,725 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 186,226 188,944 187,190 183,725 Diluted Loss per Common Share $ (0.06 ) $ (0.03 ) $ (0.10 ) $ (0.10 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 27,580 23,562 26,219 25,359

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: September 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 604,540 $ (333,904 ) $ 270,636 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 801,253 (420,114 ) 381,139 552,395 (405,317 ) 147,078 Total $ 1,405,793 $ (754,018 ) $ 651,775 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 52,000 Goodwill 1,882,244 1,222,601 Total $ 1,961,244 $ 1,274,601
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 0 $ 1,222,601 Additions arising from business acquisitions: Netsmart 0 0 615,634 615,634 Other 45,220 0 0 45,220 Total additions to goodwill 45,220 0 615,634 660,854 Reallocation 0 (37,600 ) 37,600 0 Foreign exchange translation (1,211 ) 0 0 (1,211 ) Balance as of September 30, 2016 $ 840,376 $ 388,634 $ 653,234 $ 1,882,244

Asset Impairment Charges (Table

Asset Impairment Charges (Tables)	9 Months Ended
	Sep. 30, 2016
Asset Impairment Charges [Abstract]
Asset Impairment Charges	We incurred the following impairment charges: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Asset impairment charges $ 0 $ 22 $ 4,650 $ 341

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consisted of the following: September 30, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 52,370 $ 292,630 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility 387,500 5,027 382,473 346,875 5,704 341,171 Netsmart Non-Recourse Debt: First Lien Term Loan 394,013 16,720 377,293 0 0 0 Second Lien Term Loan 167,000 9,367 157,633 0 0 0 Other debt 37 0 37 183 0 183 Total debt $ 1,293,550 $ 83,484 $ 1,210,066 $ 692,058 $ 67,475 $ 624,583 Less debt payable within one year - excluding Netsmart 12,538 487 12,051 12,657 479 12,178 Less debt payable within one year - Netsmart 3,950 2,613 1,337 0 0 0 Total long-term debt, less current maturities $ 1,277,062 $ 80,384 $ 1,196,678 $ 679,401 $ 66,996 $ 612,405
Interest Expense	Interest expense consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Interest expense $ 3,896 $ 4,370 $ 11,029 $ 12,239 Amortization of discounts and debt issuance costs 3,522 3,508 10,401 10,321 Write off of unamortized deferred debt issuance costs 0 1,376 0 1,433 Netsmart: Interest expense (1) 11,019 0 19,549 0 Amortization of discounts and debt issuance costs 930 0 1,778 0 Total interest expense $ 19,367 $ 9,254 $ 42,757 $ 23,993 (1) Includes interest expense related to capital leases.
Summary of Future Payment Obligations under Debt	The following table summarizes our future payment obligations under our debt as of September 30, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 $ 0 Term Loan 237,500 3,125 15,625 28,125 40,625 150,000 0 Revolving Facility 150,000 0 0 0 0 150,000 0 Netsmart Non-Recourse Debt: First Lien Term Loan 394,013 988 3,952 3,952 3,952 3,952 377,217 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Other debt 37 37 0 0 0 0 0 Total debt $ 1,293,550 $ 4,150 $ 19,577 $ 32,077 $ 44,577 $ 648,952 $ 544,217 (1)
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense	Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 3,234 $ 3,234 Amortization of discounts and debt issuance costs 3,185 3,035 9,401 8,960 Total interest expense related to the 1.25% Notes $ 4,263 $ 4,113 $ 12,635 $ 12,194

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Loss before income taxes $ (2,499 ) $ (1,441 ) $ (2,448 ) $ (14,250 ) Income tax benefit (provision) $ 2,656 $ (3,692 ) $ 2,596 $ (4,183 ) Effective tax rate 106.3 % (256.2 %) 106.0 % (29.4 %)

Derivative Financial Instrume30

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: September 30, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,324 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 40,804 N/A 1.25% Embedded cash conversion option N/A Other liabilities 41,601 Total derivatives $ 42,128 $ 41,601 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2016 Nine Months Ended September 30, 2016 Foreign exchange contracts $ 971 $ 1,172 Cost of Revenue $ 88 $ 84 Selling, general and administrative expenses 71 68 Research and development 126 120 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Foreign exchange contracts $ (317 ) $ (87 ) Cost of Revenue $ (29 ) $ (29 ) Selling, general and administrative expenses (23 ) (23 ) Research and development (40 ) (40 )
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 1.25% Call Option $ 2,306 $ (18,277 ) $ (39,404 ) $ (8,422 ) 1.25% Embedded cash conversion option (2,362 ) 18,404 39,609 8,390 Net gain (loss) included in other income, net $ (56 ) $ 127 $ 205 $ (32 )

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Marketable Securities (3) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (49 ) (8,365 ) 710 (7,704 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 (165 ) (165 ) Net other comprehensive (loss) income (49 ) (8,365 ) 545 (7,869 ) Balance as of September 30, 2016 (2) $ (4,549 ) $ (8,365 ) $ 803 $ (12,111 ) (1) (2) (3) Marketable securities represent NantHealth common stock (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive (loss) income before reclassifications (1,873 ) 0 (53 ) (1,926 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 56 (84 ) Net other comprehensive (loss) income (1,873 ) (140 ) 3 (2,010 ) Balance as of September 30, 2015 (2) $ (3,992 ) $ 0 $ 3 $ (3,989 ) (1) (2)
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended September 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 150 $ 0 $ 150 $ (1,482 ) $ 0 $ (1,482 ) Marketable securities: Net gain arising during the period 9,750 0 9,750 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on marketable securities 9,750 0 9,750 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period 971 (382 ) 589 (317 ) 124 (193 ) Net (gains) losses reclassified into income (285 ) 112 (173 ) 92 (36 ) 56 Net change in unrealized (losses) gains on foreign exchange contracts 686 (270 ) 416 (225 ) 88 (137 ) Net (loss) gain on cash flow hedges 686 (270 ) 416 (225 ) 88 (137 ) Other comprehensive (loss) income $ 10,586 $ (270 ) $ 10,316 $ (1,707 ) $ 88 $ (1,619 ) Nine Months Ended September 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (49 ) $ 0 $ (49 ) $ (1,873 ) $ 0 $ (1,873 ) Marketable securities: Net loss arising during the period (8,365 ) 0 (8,365 ) 0 0 0 Net (gain) loss reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized (losses) gains on marketable securities (8,365 ) 0 (8,365 ) (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 1,172 (462 ) 710 (87 ) 34 (53 ) Net (gains) losses reclassified into income (272 ) 107 (165 ) 92 (36 ) 56 Net change in unrealized gains (losses) on foreign exchange contracts 900 (355 ) 545 5 (2 ) 3 Net gain (loss) on cash flow hedges 900 (355 ) 545 5 (2 ) 3 Other comprehensive loss $ (7,514 ) $ (355 ) $ (7,869 ) $ (2,096 ) $ 86 $ (2,010 )

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2016 2015 2016 2015 Revenue: Clinical and Financial Solutions $ 276,503 $ 284,677 $ 829,656 $ 830,743 Population Health 61,722 54,405 171,347 165,038 Netsmart 52,621 0 96,854 0 Unallocated Amounts 1,538 15,394 26,606 44,965 Total revenue $ 392,384 $ 354,476 $ 1,124,463 $ 1,040,746 Gross Profit: Clinical and Financial Solutions $ 113,677 $ 120,855 $ 348,548 $ 331,828 Population Health 46,337 37,179 125,717 110,049 Netsmart 17,378 0 32,324 0 Unallocated Amounts (11,233 ) (4,686 ) (21,848 ) (15,115 ) Total gross profit $ 166,159 $ 153,348 $ 484,741 $ 426,762 Income (loss) from operations: Clinical and Financial Solutions $ 59,921 $ 66,184 $ 187,676 $ 166,607 Population Health 32,977 24,182 82,913 67,942 Netsmart (6,426 ) 0 (8,829 ) 0 Unallocated Amounts (69,598 ) (81,497 ) (214,416 ) (225,784 ) Total income (loss) from operations $ 16,874 $ 8,869 $ 47,344 $ 8,765

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($)	Apr. 19, 2016	Sep. 30, 2016	Sep. 30, 2016
Business Acquisition [Line Items]
Contribution and investment agreement date			Mar. 20, 2016
Description of liquidation preference			The liquidation preference is equal to the greater of (i) a return of the original issue price plus a preferred return (accruing on a daily basis at the rate of 11% per annum and compounding annually on the last day of each calendar year) or (ii) the as-converted value of Class A Common Units in Nathan.
Preferred return percentage			11.00%
Percentage of redemption preference		11.00%	11.00%
Equity ownership percentage	49.10%
Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 0	$ 4,100,000
GI Partners [Member]
Business Acquisition [Line Items]
Minority interest percentage	47.20%
Netsmart Management [Member]
Business Acquisition [Line Items]
Minority interest percentage	3.70%
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date			Apr. 19, 2016
Business combination, purchase price	$ 950,000,000
Equity ownership percentage	49.10%
Business combination, aggregate consideration	$ 937,066,000
Extinguishment of debt	325,000,000
Accrued interest and fees	2,000,000
Increase in Intangible asset acquired		12,000,000
Increase in deferred taxes, net acquired		4,400,000
Decrease in accrued expenses acquired		(2,000,000)
Decrease in the residual allocation to goodwill		$ 9,600,000
Netsmart [Member] | Nathan [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration	937,000,000
Netsmart [Member] | Homecare Business [Member]
Business Acquisition [Line Items]
Escrow deposit related to the integration of homecare business	$ 15,000,000
Escrow deposit period	5 years

Schedule of Purchase Price Fund

Schedule of Purchase Price Funded by the Sources of Funds (Detail) - USD ($) $ in Thousands	Apr. 19, 2016	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Cash contribution for redeemable convertible non-controlling interest		$ 333,606	$ 0
Netsmart [Member]
Business Acquisition [Line Items]
Net borrowings under new term loans	$ 534,135
Business combination, aggregate consideration	937,066
Netsmart [Member] | GI Partners [Member]
Business Acquisition [Line Items]
Cash contribution for redeemable convertible non-controlling interest	333,606
Netsmart [Member] | Netsmart Inc Management [Member]
Business Acquisition [Line Items]
Exchange of Netsmart common stock for redeemable convertible non-controlling interest	25,543
Netsmart [Member] | Allscripts [Member]
Business Acquisition [Line Items]
Cash contribution from borrowings under revolver in exchange for common stock	$ 43,782

Assets Acquired and Liabilities

Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Intangible assets	$ 409,500
Goodwill	1,882,244	$ 1,222,601
Netsmart [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	5,982
Accounts receivable, net	54,042
Prepaid expenses and other current assets	9,335
Fixed assets	26,829
Intangible assets	409,500
Goodwill	615,634
Other assets	6,889
Accounts payable	(14,151)
Accrued expenses	(9,595)
Deferred revenue	(18,843)
Capital lease obligations	(17,833)
Deferred taxes, net	(127,050)
Other liabilities	(3,673)
Net assets acquired	$ 937,066

Acquired Intangible Assets Amor

Acquired Intangible Assets Amortization (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 409,500
Corporate Trademark [member]
Business Acquisition [Line Items]
Indefinite intangible assets, fair value	27,000
Technology [member]
Business Acquisition [Line Items]
Intangible assets, fair value	$ 144,000
Product Trademarks [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	10 years
Intangible assets, fair value	$ 8,500
Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, fair value	$ 230,000
Minimum [Member] | Technology [member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	10 years
Minimum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	12 years
Maximum [Member] | Technology [member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	12 years
Maximum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	20 years

Pro forma Results (Detail)

Pro forma Results (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Netsmart [Member]
Business Acquisition [Line Items]
Revenue	[1]	$ 52,621	$ 0	$ 96,855	$ 0
Net loss	[1]	(11,126)	0	(18,239)	0
Combined Entity [Member]
Business Acquisition [Line Items]
Revenue		399,811	400,819	1,198,048	1,157,087
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders		$ (5,147)	$ (21,223)	$ (34,862)	$ (88,933)
Loss per share, basic and diluted		$ (0.03)	$ (0.11)	$ (0.19)	$ (0.48)
[1]	Amounts are not adjusted for the effects of transactions between us and Netsmart.

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term marketable securities	$ 197,250	$ 0
Prepaid expenses and other current assets	112,416	93,622
Accrued expenses	(85,336)	(62,021)
Total	197,777	(578)
NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term marketable securities	197,250	0
Foreign exchange derivative assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Prepaid expenses and other current assets	1,324	424
Foreign exchange derivative liabilities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Accrued expenses	0	0
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other liabilities	(41,601)	(81,210)
1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other assets	40,804	80,208
Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total	197,250	0
Level 1 [Member] | NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term marketable securities	197,250	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Accrued expenses	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total	1,324	424
Level 2 [Member] | NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term marketable securities	0	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Prepaid expenses and other current assets	1,324	424
Level 2 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Accrued expenses	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total	(797)	(1,002)
Level 3 [Member] | NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term marketable securities	0	0
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Accrued expenses	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other liabilities	(41,601)	(81,210)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other assets	$ 40,804	$ 80,208

Fair Value Measurements and I39

Fair Value Measurements and Investments - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		Sep. 08, 2016	Jun. 02, 2016	Jun. 01, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Goodwill					$ 1,882,244				$ 1,882,244		$ 1,222,601
Common stock, shares issued					267,868,000				267,868,000		266,545,000
Carrying values of equity method investment	[1]				$ 2,436				$ 2,436		$ 205,553
Closing price of fair value investment					197,250				197,250		0
Unrealized loss of fair value investment					10,316			$ (1,619)	(7,869)	$ (2,010)
Asset impairment charges					0		$ 4,650	$ 22	4,650	341
Total consideration for non-marketable convertible note of a third party							500
Total consideration for non marketable equity securities						$ 10,200			20,685	$ 212,654
Carrying values of cost method investments					$ 26,041				$ 26,041		$ 17,876
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate					1.25%				1.25%
Other Assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Convertible note fair value					$ 500				$ 500
Carrying values of cost method investments					10,200				$ 10,200
Cost Method Equity Investments
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset impairment charges							$ 2,100
NantHealth, Inc [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common Stock shares voting percent			12.40%						12.40%
Aggregate voting interest on common stock			15,000,000
Carrying values of equity method investment					205,600				$ 205,600
NantHealth, Inc [Member] | IPO [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares issued			6,500,000	14,285,714
Common Stock shares voting percent			11.80%	12.60%
Additional shares purchased			714,286
Additional shares purchased per share			$ 14
Additional shares purchased investment amount			$ 10,000
NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Closing price of fair value investment					$ 197,300				197,300
Unrealized loss of fair value investment									$ 8,400
Third Party
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Majority interest acquired in a third party		$ 29,000
Goodwill		45,200
Intangible assets		21,400
Estimated fair value of non controlling interest		$ 29,400
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Summary of Equity Investments I

Summary of Equity Investments Included in Other Assets (Detail) $ in Thousands		9 Months Ended
		Sep. 30, 2016USD ($)Investment	Dec. 31, 2015USD ($)
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	3
Equity method investments, Original Investment	[1]	$ 1,658
Equity method investments, Carrying Value	[1]	$ 2,436	$ 205,553
Cost method investments, Number of Investees | Investment		5
Cost method investments, Original Investment		$ 29,991
Cost method investments, Carrying Value		$ 26,041	17,876
Total equity investments, Number of Investees | Investment		8
Total equity investments, Original Investment		$ 31,649
Total equity investments, Carrying Value		$ 28,477	223,429
Nant Health, LLC [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1],[2]	0
Equity method investments, Original Investment	[1],[2]	$ 0
Equity method investments, Carrying Value	[1],[2]	$ 0	203,117
Other [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	3
Equity method investments, Original Investment	[1]	$ 1,658
Equity method investments, Carrying Value	[1]	$ 2,436	$ 2,436
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.
[2]	As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method.

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Jun. 30, 2016Installment$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	Dec. 31, 2015$ / sharesshares	Nov. 30, 2015USD ($)
Class Of Stock [Line Items]
Capitalized stock-based compensation costs | $		$ 0	$ 0		$ 0	$ 0
Stock options granted		0	0		0	0
Share issued, exercise of options and release of stock awards					1,300,000		1,400,000
Shares settled for tax withholding					572,000	433,000
Stock repurchase program, authorized amount | $								$ 150,000,000
Common stock repurchased, shares		1,500,000			5,500,000
Common stock repurchased, amount | $		$ 19,000,000			$ 71,082,000	$ 0
Remaining value for purchase of common stock under the stock repurchase program | $		$ 79,000,000		$ 79,000,000	$ 79,000,000
Unregistered common stock, shares issued		267,868,000		267,868,000	267,868,000		266,545,000
Common stock, par value | $ / shares		$ 0.01		$ 0.01	$ 0.01		$ 0.01
Stock based compensation expense | $		$ 9,773,000	$ 9,192,000		$ 30,834,000	$ 28,728,000
Netsmart [Member]
Class Of Stock [Line Items]
Stock based compensation expense | $		1,724,000			3,150,000
Liability for outstanding awards | $		$ 3,200,000		$ 3,200,000	$ 3,200,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model | $ / shares		$ 0.45		$ 0.45	$ 0.45
Estimated share price | $ / shares		$ 1		$ 1	$ 1
Share based compensation expense remaining to be recognized | $		$ 25,400,000		$ 25,400,000	$ 25,400,000
Share based compensation expense remaining to be recognized, 2016 | $		1,800,000		1,800,000	1,800,000
Share based compensation expense remaining to be recognized, 2017 | $		7,100,000		7,100,000	7,100,000
Share based compensation expense remaining to be recognized, 2018 | $		7,100,000		7,100,000	7,100,000
Share based compensation expense remaining to be recognized, 2019 | $		7,100,000		7,100,000	7,100,000
Share based compensation expense remaining to be recognized, 2020 | $		2,300,000		$ 2,300,000	2,300,000
Netsmart [Member] | Class B Non Voting Common Units
Class Of Stock [Line Items]
Options issued during the period				89,889,000
Exercise price | $ / shares				$ 1
Intrinsic value related to outstanding Option Units | $		$ 0		$ 0	$ 0
Estimated weighted average fair value, Black-Scholes-Merton option pricing model | $ / shares		$ 0.45		$ 0.45	$ 0.45
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Class Of Stock [Line Items]
Stock options granted				89,889,000
Maximum issuance of options		116,491,000		116,491,000	116,491,000
Options available for further issuance		27,986,000		27,986,000	27,986,000
Exercise price | $ / shares				$ 1
Option Units, Forfeited during the period				1,384,000
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Time Based Option Units [Member]
Class Of Stock [Line Items]
Options issued during the period				64,198,000
Exercise price | $ / shares				$ 1
Option Units, Forfeited during the period				989,000
Options vesting period				4 years
Vesting description					The Option Units vest ratably over a period of four years, with the first twenty-five percent vesting at the first anniversary of the issuance and the remaining vesting in equal monthly increments over the following thirty-six months
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Performance Based Option Units [Member]
Class Of Stock [Line Items]
Options issued during the period				25,691,000
Exercise price | $ / shares				$ 1
Option Units, Forfeited during the period				395,000
Stock based compensation expense | $					$ 0
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Maximum [Member]
Class Of Stock [Line Items]
Option Units expiration period					10 years
Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of installments | Installment	4
Number of warrants vesting annually	750,000
Warrant expiration period	2026-06
Case 1 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued	900,000
Common stock, par value | $ / shares	$ 0.01
Sale of common stock, price per share | $ / shares	$ 12.47
Case 2 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued	1,000,000
Sale of common stock, price per share | $ / shares	$ 14.34
Case 3 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued	1,100,000
Sale of common stock, price per share | $ / shares	$ 15.59

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 9,773	$ 9,192	$ 30,834	$ 28,728
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,863	1,796	6,721	6,801
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	979	972	3,209	3,247
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	884	824	3,512	3,554
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	6,464	5,649	17,972	15,860
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 1,446	$ 1,747	$ 6,141	$ 6,067

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	24	3,185
Weighted-Average Grant Date Fair Value, granted	$ 13.16	$ 13.12
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	24	2,019
Weighted-Average Grant Date Fair Value, granted	$ 13.16	$ 13.14
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	545
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 12.39
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	621
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 13.68

Summary of the Activity Under t

Summary of the Activity Under the Plan (Detail) - $ / shares	3 Months Ended		5 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option Units, Granted during the period	0	0		0	0
Netsmart [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option Units, Granted during the period			89,889,000
Option Units, Options called during the period			0
Option Units, Options exercised during the period			0
Option Units, Forfeited during the period			1,384,000
Option Units, Outstanding – September 30, 2016	88,505,000		88,505,000	88,505,000
Option Units, Exercisable – September 30, 2016	0		0	0
Weighted Average Exercise Price, Granted during the period			$ 1
Weighted Average Exercise Price, Options called during the period			0
Weighted Average Exercise Price, Options exercised during the period			0
Weighted Average Exercise Price, Forfeited during the period			1
Weighted Average Exercise Price, Outstanding – September 30, 2016	$ 1		1	$ 1
Weighted Average Exercise Price, Exercisable – September 30, 2016	$ 0		$ 0	$ 0

Schedule of Option Units Outsta

Schedule of Option Units Outstanding (Detail) - Netsmart [Member]	5 Months Ended
	Sep. 30, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, Average Black-Scholes Value	$ 0.45
Class B Non Voting Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 1
Option Units, Outstanding – September 30, 2016 | shares	88,505,000
Outstanding, Average Black-Scholes Value	$ 0.45
Outstanding, Weighted Average Remaining Life	6 years 6 months 22 days
Option Units, Exercisable – September 30, 2016 | shares	0
Exercisable, Average Black-Scholes Value	$ 0
Exercisable, Weighted Average Remaining Life	0 years

Schedule of Compensation Expens

Schedule of Compensation Expense Categories in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	$ 9,773	$ 9,192	$ 30,834	$ 28,728
Cost of revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	1,863	1,796	6,721	6,801
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	1,446	$ 1,747	6,141	$ 6,067
Netsmart [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	1,724		3,150
Netsmart [Member] | Cost of revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	64		126
Netsmart [Member] | Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	43		79
Netsmart [Member] | Selling and Marketing Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	81		174
Netsmart [Member] | General and Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation expense	$ 1,536		$ 2,771

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Units Weighted Average Assumptions (Detail) - Netsmart [Member] - Class B Non Voting Common Units	5 Months Ended
	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Average expected term in years	6 years 6 months 22 days
Risk free rate (weighted average)	1.40%
Expected dividends	0.00%
Average volatility	43.80%

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Basic Loss per Common Share:
Net income (loss)	$ 157	$ (5,133)	$ 148	$ (18,433)
Less: Net income attributable to non-controlling interest	(151)	(111)	(142)	(120)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest	(10,191)	0	(18,344)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,185)	$ (5,244)	$ (18,338)	$ (18,553)
Weighted-average common shares outstanding	186,226	188,944	187,190	183,725
Basic Loss per Common Share	$ (0.06)	$ (0.03)	$ (0.10)	$ (0.10)
Diluted Loss per Common Share:
Net income (loss)	$ 157	$ (5,133)	$ 148	$ (18,433)
Less: Net income attributable to non-controlling interest	(151)	(111)	(142)	(120)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest	(10,191)	0	(18,344)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,185)	$ (5,244)	$ (18,338)	$ (18,553)
Weighted-average common shares outstanding	186,226	188,944	187,190	183,725
Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	186,226	188,944	187,190	183,725
Diluted Loss per Common Share	$ (0.06)	$ (0.03)	$ (0.10)	$ (0.10)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	27,580	23,562	26,219	25,359

Goodwill and Intangible Asset50

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,405,793	$ 1,003,247
Accumulated Amortization	(754,018)	(707,601)
Intangible Assets, Net	651,775	295,646
Registered trademarks	79,000	52,000
Goodwill	1,882,244	1,222,601
Total	1,961,244	1,274,601
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	604,540	450,852
Accumulated Amortization	(333,904)	(302,284)
Intangible Assets, Net	270,636	148,568
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	801,253	552,395
Accumulated Amortization	(420,114)	(405,317)
Intangible Assets, Net	$ 381,139	$ 147,078

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Goodwill [Line Items]
Goodwill	$ 1,222,601
Additions arising from business acquisitions	660,854
Reallocation	0
Foreign exchange translation	(1,211)
Goodwill, net	1,882,244
Other Acquisitions [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	45,220
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	796,367
Additions arising from business acquisitions	45,220
Reallocation	0
Foreign exchange translation	(1,211)
Goodwill, net	840,376
Clinical and Financial Solutions [Member] | Other Acquisitions [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	45,220
Population Health [Member]
Goodwill [Line Items]
Goodwill	426,234
Additions arising from business acquisitions	0
Reallocation	(37,600)
Foreign exchange translation	0
Goodwill, net	388,634
Population Health [Member] | Other Acquisitions [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Netsmart [Member]
Goodwill [Line Items]
Goodwill	0
Additions arising from business acquisitions	615,634
Reallocation	37,600
Foreign exchange translation	0
Goodwill, net	$ 653,234

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule Of Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses associated with goodwill	$ 0	$ 0
Goodwill recognized	660,854,000
Netsmart [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill recognized	$ 615,634,000

Asset Impairment Charges (Detai

Asset Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Asset Impairment Charges [Abstract]
Asset impairment charges	$ 0	$ 4,650	$ 22	$ 4,650	$ 341

Asset Impairment Charges - Addi

Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Asset Impairment Charges [Line Items]
Asset impairment charges	$ 0	$ 4,650	$ 22	$ 4,650	$ 341
Other charges		400
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges		2,200
Cost Method Equity Investments
Asset Impairment Charges [Line Items]
Asset impairment charges		$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Principal Balance	$ 1,293,550		$ 692,058
Unamortized Discount and Debt Issuance Costs	83,484		67,475
Net Carrying Amount	1,210,066		624,583
Principal Balance, Current	12,538		12,657
Unamortized Discount and Debt Issuance Costs, Current	487		479
Net Carrying Amount, Current	12,051		12,178
Principal Balance, Noncurrent	1,277,062		679,401
Unamortized Discount and Debt Issuance Costs, Noncurrent	80,384		66,996
Net Carrying Amount, Noncurrent	1,196,678		612,405
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	3,950		0
Unamortized Discount and Debt Issuance Costs, Current	2,613		0
Net Carrying Amount, Current	1,337		0
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	52,370		61,771
Net Carrying Amount	292,630		283,229
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	387,500		346,875
Unamortized Discount and Debt Issuance Costs	5,027		5,704
Net Carrying Amount	382,473		341,171
Netsmart Non-Recourse Debt First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	394,013		0
Unamortized Discount and Debt Issuance Costs	16,720		0
Net Carrying Amount	377,293		0
Netsmart Non-Recourse Debt Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		0
Unamortized Discount and Debt Issuance Costs	9,367		0
Net Carrying Amount	157,633		0
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	37		183
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 37		$ 183
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Interest expense		$ 3,896	$ 4,370	$ 11,029	$ 12,239
Amortization of discounts and debt issuance costs		3,522	3,508	10,401	10,321
Write off of unamortized deferred debt issuance costs		0	1,376	0	1,433
Total interest expense		19,367	9,254	42,757	23,993
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		930	0	1,778	0
Interest expense	[1]	$ 11,019	$ 0	$ 19,549	$ 0
[1]	Includes interest expense related to capital leases.

Interest Expense Related to Not

Interest Expense Related to Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 3,896	$ 4,370	$ 11,029	$ 12,239
Amortization of discounts and debt issuance costs	3,522	3,508	10,401	10,321
Total interest expense	19,367	9,254	42,757	23,993
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Coupon interest at 1.25%	1,078	1,078	3,234	3,234
Amortization of discounts and debt issuance costs	3,185	3,035	9,401	8,960
Total interest expense	$ 4,263	$ 4,113	$ 12,635	$ 12,194

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Apr. 19, 2016	Sep. 30, 2016		Mar. 31, 2019	Dec. 31, 2015
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,293,550,000			$ 692,058,000
Allscripts Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		237,500,000
Allscripts Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		150,000,000
Letters of credit outstanding		800,000
Credit facility, amount available		$ 399,200,000
Allscripts Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		2.52%
Allscripts Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		2.00%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 345,000,000	[1]		$ 345,000,000
Interest rate		1.25%
Netsmart First Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		5.75%
Netsmart First Lien Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Leverage ratio		8.75%
Netsmart First Lien Credit Agreement [Member] | Scenario Forecast [Member] | Minimum [Member]
Debt Instrument [Line Items]
Leverage ratio				6.75%
Netsmart First Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,500,000
Credit facility, amount available		48,500,000
Credit facility, maximum borrowing capacity	$ 50,000,000
Senior secured credit facilities term, years	5 years
Credit facility termination date	Apr. 19, 2021
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 394,000,000
Credit facility, maximum borrowing capacity	$ 395,000,000
Senior secured credit facilities term, years	7 years
Credit facility termination date	Apr. 19, 2023
Netsmart First Lien Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	4.75%	4.75%
Netsmart First Lien Credit Agreement [Member] | LIBOR Rate [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	4.25%
Netsmart First Lien Credit Agreement [Member] | Alternate Base Rate Loans [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	3.75%
Netsmart First Lien Credit Agreement [Member] | Alternate Base Rate Loans [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	3.25%
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		10.50%
Netsmart Second Lien Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Leverage ratio		9.75%
Netsmart Second Lien Credit Agreement [Member] | Scenario Forecast [Member] | Minimum [Member]
Debt Instrument [Line Items]
Leverage ratio				7.75%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 167,000,000
Credit facility, maximum borrowing capacity	$ 167,000,000
Senior secured credit facilities term, years	7 years 6 months
Credit facility termination date	Oct. 19, 2023
Netsmart Second Lien Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		9.50%
Netsmart Second Lien Credit Agreement [Member] | LIBOR Rate [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	9.50%
Netsmart Second Lien Credit Agreement [Member] | Alternate Base Rate Loans [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	8.50%
Netsmart Credit Agreements [Member]
Debt Instrument [Line Items]
Debt issuance costs capitalized		$ 27,900,000
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Oblig

Summary of Future Payment Obligations under Debt (Detail) - USD ($) $ in Thousands		Sep. 30, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Total		$ 1,293,550		$ 692,058
Remainder of 2016		4,150
2,017		19,577
2,018		32,077
2,019		44,577
2,020		648,952
Thereafter		544,217
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	345,000
Remainder of 2016	[1]	0
2,017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
Thereafter	[1]	0
Term Loan [Member]
Debt Instrument [Line Items]
Total		237,500
Remainder of 2016		3,125
2,017		15,625
2,018		28,125
2,019		40,625
2,020		150,000
Thereafter		0
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		394,013
Remainder of 2016		988
2,017		3,952
2,018		3,952
2,019		3,952
2,020		3,952
Thereafter		377,217
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000
Remainder of 2016		0
2,017		0
2,018		0
2,019		0
2,020		0
Thereafter		167,000
Other Debt [Member]
Debt Instrument [Line Items]
Total		37		$ 183
Remainder of 2016		37
2,017		0
2,018		0
2,019		0
2,020		0
Thereafter		0
Revolving Facility [Member]
Debt Instrument [Line Items]
Total		150,000
Remainder of 2016		0
2,017		0
2,018		0
2,019		0
2,020		150,000
Thereafter		$ 0
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Obl60

Summary of Future Payment Obligations under Debt (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2016
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (2,499)	$ (1,441)	$ (2,448)	$ (14,250)
Income tax benefit (provision)	$ 2,656	$ (3,692)	$ 2,596	$ (4,183)
Effective tax rate	106.30%	(256.20%)	106.00%	(29.40%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Valuation allowance	$ 1.4	$ 5.9	$ 1.4	$ 5.9
Cumulative operating income loss period considered			3 years
Unrecognized income tax benefits	$ 11.5		$ 11.5		$ 11.8

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 42,128	$ 80,632
Derivative liability, fair value	41,601	81,210
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	1,324	424
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	40,804	80,208
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 41,601	$ 81,210

Derivative Financial Instrume64

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2016USD ($)Derivative	Sep. 30, 2016USD ($)Derivative	Sep. 30, 2016INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	21	21	21
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 0	$ 0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	1,100,000	$ 1,100,000
Estimated period of unrealized gains included in AOCI reclassified into income		12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature		Oct. 31, 2016
Derivative notional amount outstanding	300,000	$ 300,000	₨ 20,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature		Dec. 31, 2017
Derivative notional amount outstanding	$ 1,800,000	$ 1,800,000	₨ 120,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option				$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 971	$ (317)	$ 1,172	$ (87)
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	88	(29)	84	(29)
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	71	(23)	68	(23)
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 126	$ (40)	$ 120	$ (40)

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ (56)	$ 127	$ 205	$ (32)
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	2,306	(18,277)	(39,404)	(8,422)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ (2,362)	$ 18,404	$ 39,609	$ 8,390

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,407,884
Other comprehensive (loss) income before reclassifications			(7,704)	$ (1,926)
Net losses (gains) reclassified from accumulated other comprehensive loss			(165)	(84)
Total other comprehensive income (loss)	$ 10,316	$ (1,619)	(7,869)	(2,010)
Balance at the end of the period	1,329,684		1,329,684
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,500)	(2,119)
Other comprehensive (loss) income before reclassifications			(49)	(1,873)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive income (loss)			(49)	(1,873)
Balance at the end of the period	(4,549)	(3,992)	(4,549)	(3,992)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			0	140
Other comprehensive (loss) income before reclassifications			(8,365)	0
Net losses (gains) reclassified from accumulated other comprehensive loss			0	(140)
Total other comprehensive income (loss)			(8,365)	(140)
Balance at the end of the period	(8,365)	0	(8,365)	0
Unrealized Net Gains (Losses) on Foreign Exchange Contracts [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			258	0
Other comprehensive (loss) income before reclassifications			710	(53)
Net losses (gains) reclassified from accumulated other comprehensive loss			(165)	56
Total other comprehensive income (loss)			545	3
Balance at the end of the period	803	3	803	3
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,242)	(1,979)
Balance at the end of the period	$ (12,111)	$ (3,989)	$ (12,111)	$ (3,989)

Components of Accumulated Oth68

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 521	$ 166	$ 2
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)				$ 88

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 150	$ (1,482)	$ (49)	$ (1,873)
Net change in unrealized (losses) gains on marketable securities, Before-Tax Amount	9,750	0	(8,365)	(228)
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	686	(225)	900	5
Other comprehensive (loss) income, Before-Tax Amount	10,586	(1,707)	(7,514)	(2,096)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive (loss) income, Tax Effect	(270)	88	(355)	86
Foreign currency translation adjustments, Net	150	(1,482)	(49)	(1,873)
Other comprehensive (loss) income, Net	10,316	(1,619)	(7,869)	(2,010)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Marketable securities, net gain (loss) arising during the period, Before-Tax Amount	9,750	0	(8,365)	0
Marketable securities, net (gain) loss reclassified into income, Before-Tax Amount	0	0	0	(228)
Net change in unrealized (losses) gains on marketable securities, Before-Tax Amount	9,750	0	(8,365)	(228)
Marketable securities, net gain (loss) arising during the period, Tax Effect	0	0	0	0
Marketable securities, net (gain) loss reclassified into income, Tax Effect	0	0	0	88
Net change in unrealized (losses) gains on marketable securities, Tax Effect	0	0	0	88
Marketable securities, net gain (loss) arising during the period, Net	9,750	0	(8,365)	0
Marketable securities, net (gain) loss reclassified into income, Net	0	0	0	(140)
Net change in unrealized (losses) gains on marketable securities, Net	9,750	0	(8,365)	(140)
Other comprehensive (loss) income, Net			(8,365)	(140)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	686	(225)	900	5
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(270)	88	(355)	(2)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	416	(137)	545	3
Other comprehensive (loss) income, Net			545	3
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	971	(317)	1,172	(87)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(285)	92	(272)	92
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	686	(225)	900	5
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	(382)	124	(462)	34
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	112	(36)	107	(36)
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(270)	88	(355)	(2)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	589	(193)	710	(53)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(173)	56	(165)	56
Derivatives qualifying as cash flow hedges, net gain (loss), Net	$ 416	$ (137)	$ 545	$ 3

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Pending Litigation [Member] - $ / Violation	9 Months Ended
	Sep. 30, 2016	May 01, 2012
Pegasus Imaging Corporation [Member]
Loss Contingencies [Line Items]
Contingency allegations	The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud and negligence
Loss contingency action taken by defendant	Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation.
Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA		500

Business Segments - Additional

Business Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Number of operating segments	7

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 392,384	$ 354,476	$ 1,124,463	$ 1,040,746
Gross Profit	166,159	153,348	484,741	426,762
Income (loss) from operations	16,874	8,869	47,344	8,765
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	1,538	15,394	26,606	44,965
Gross Profit	(11,233)	(4,686)	(21,848)	(15,115)
Income (loss) from operations	(69,598)	(81,497)	(214,416)	(225,784)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	276,503	284,677	829,656	830,743
Gross Profit	113,677	120,855	348,548	331,828
Income (loss) from operations	59,921	66,184	187,676	166,607
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	61,722	54,405	171,347	165,038
Gross Profit	46,337	37,179	125,717	110,049
Income (loss) from operations	32,977	24,182	82,913	67,942
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	52,621	0	96,854	0
Gross Profit	17,378	0	32,324	0
Income (loss) from operations	$ (6,426)	$ 0	$ (8,829)	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016	Oct. 14, 2016	Apr. 19, 2016
Subsequent Event [Line Items]
Percentage of interests acquired			49.10%
Date of acquisition	Oct. 14, 2016
Netsmart [Member]
Subsequent Event [Line Items]
Percentage of interests acquired			49.10%
Date of acquisition	Oct. 27, 2016
Subsequent Event [Member]
Subsequent Event [Line Items]
Percentage of interests acquired		100.00%